NasdaqGS - Delayed Quote USD
Geron Corporation (GERN)
1.4300
-0.0900
(-5.92%)
At close: 4:00:02 PM EDT
1.4400
+0.01
+(0.70%)
After hours: 6:47:41 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Dawn Carter Bir | Interim President & Chief Executive Officer and Director | 64.16k | -- | 1971 |
| Ms. Michelle J. Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | 846.38k | -- | 1967 |
| Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO | 977.48k | 1.91M | 1964 |
| Mr. James Ziegler M.B.A. | Executive VP & Chief Commercial Officer | 618.67k | -- | 1966 |
| Dr. Joseph Emile Eid M.D. | Executive Vice President of Research & Development | 304.1k | -- | 1967 |
| Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Mr. Scott Samuels | Executive VP, Chief Legal Officer & Secretary | 485.32k | -- | -- |
| Ms. Shannon T. Odam | Executive VP & Chief People Officer | -- | -- | 1975 |
| Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer | -- | -- | 1983 |
Geron Corporation
919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 229
Description
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Corporate Governance
Geron Corporation’s ISS Governance QualityScore as of June 1, 2025 is 6. The pillar scores are Audit: 6; Board: 2; Shareholder Rights: 9; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 6, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC
Geron Corporation Earnings Date
Recent Events
Related Tickers
AGEN Agenus Inc.
4.1300
+20.41%
LCTX Lineage Cell Therapeutics, Inc.
0.6650
+0.05%
MAIA MAIA Biotechnology, Inc.
1.7500
-2.23%
ADMA ADMA Biologics, Inc.
20.43
+2.97%
IOVA Iovance Biotherapeutics, Inc.
1.7600
+0.57%
INCY Incyte Corporation
65.31
+0.38%
IBRX ImmunityBio, Inc.
2.6700
+0.38%
FATE Fate Therapeutics, Inc.
1.3000
+7.44%
HUMA Humacyte, Inc.
2.6200
-1.87%
LXRX Lexicon Pharmaceuticals, Inc.
0.6216
-0.80%